Proteomics-based prediction of clinical response in acute myeloid leukemia.
about
Prediction of individual response to anticancer therapy: historical and future perspectivesMass spectrometry-based proteomics and its potential use in haematological research.Exploratory proteomic analysis of hypobaric hypoxia and acute mountain sickness in humans.A new frontier in personalized cancer therapy: mapping molecular changes.Proteomics approaches for myeloid leukemia drug discovery.Pharmacometabolomics identifies dodecanamide and leukotriene B4 dimethylamide as a predictor of chemosensitivity for patients with acute myeloid leukemia treated with cytarabine and anthracycline.
P2860
Proteomics-based prediction of clinical response in acute myeloid leukemia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Proteomics-based prediction of clinical response in acute myeloid leukemia.
@ast
Proteomics-based prediction of clinical response in acute myeloid leukemia.
@en
type
label
Proteomics-based prediction of clinical response in acute myeloid leukemia.
@ast
Proteomics-based prediction of clinical response in acute myeloid leukemia.
@en
prefLabel
Proteomics-based prediction of clinical response in acute myeloid leukemia.
@ast
Proteomics-based prediction of clinical response in acute myeloid leukemia.
@en
P2093
P50
P1476
Proteomics-based prediction of clinical response in acute myeloid leukemia.
@en
P2093
Amber C Donahue
Elihu H Estey
Francis J Giles
Iman Jilani
Steven J Potts
P304
P356
10.1016/J.EXPHEM.2009.03.011
P577
2009-05-05T00:00:00Z